Tardive dyskinesia

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.Full text

Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry. 2019 Jun;64(6):388-99.Full text  Abstract

Caroff SN, Citrome L, Meyer J, et al. A modified Delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia. J Clin Psychiatry. 2020 Jan 28;81(2):19cs12983. Abstract

Bhidayasiri R, Jitkritsadakul O, Friedman JH, et al. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018 Jun 15;389:67-75. Abstract

1. Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018 Jun 15;389:35-42. Abstract

2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.Full text

3. Friedman JH. Tardive syndromes. Continuum (Minneap Minn). 2019 Aug;25(4):1081-98. Abstract

4. Bashir HH, Jankovic J. Treatment of tardive dyskinesia. Neurol Clin. 2020 May;38(2):379-96. Abstract

5. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013 Jul 12:3:tre-03-161-4138-1.Full text  Abstract

6. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020 Sep 1;177(9):868-72.Full text  Abstract

7. Vinuela A, Kang UJ. Reversibility of tardive dyskinesia syndrome. Tremor Other Hyperkinet Mov (N Y). 2014 Nov 27:4:282.Full text  Abstract

8. Carbon M, Hsieh CH, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017 Mar;78(3):e264-78. Abstract

9. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008 Mar;21(2):151-6. Abstract

10. Mori Y, Takeuchi H, Tsutsumi Y. Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan. Ther Adv Psychopharmacol. 2022 Dec 26:12:20451253221139608.Full text  Abstract

11. Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry. 2019 Jun;64(6):388-99.Full text  Abstract

12. Caroff SN, Citrome L, Meyer J, et al. A modified Delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia. J Clin Psychiatry. 2020 Jan 28;81(2):19cs12983. Abstract

13. D'Abreu A, Friedman JH. Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent: literature review. Tremor Other Hyperkinet Mov (N Y). 2018 Aug 31:8:570.Full text  Abstract

14. Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012 Sep 1;27(10):1205-15. Abstract

15. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. Abstract

16. Jeste DV, Wyatt RJ. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity? J Clin Psychiatry. 1981 Dec;42(12):455-7. Abstract

17. Gunne LM, Häggström JE, Sjöquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature. 1984 May 24-30;309(5966):347-9. Abstract

18. Novick D, Haro JM, Bertsch J, et al. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010 Oct;30(5):531-40. Abstract

19. Andrew HG. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia. Can J Psychiatry. 1994 Nov;39(9 suppl 2):S76-80. Abstract

20. Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance use disorders. Am J Drug Alcohol Abuse. 1990;16(1-2):57-66. Abstract

21. Bailey LG, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients. Psychopharmacol Bull. 1997;33(1):177-81. Abstract

22. Turrone P, Seeman MV, Silvestri S. Estrogen receptor activation and tardive dyskinesia. Can J Psychiatry. 2000 Apr;45(3):288-90. Abstract

23. Yassa R, Lal S, Korpassy A, et al. Nicotine exposure and tardive dyskinesia. Biol Psychiatry. 1987 Jan;22(1):67-72. Abstract

24. Wonodi I, Adami HM, Cassady SL, et al. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J Clin Psychopharmacol. 2004 Dec;24(6):592-8. Abstract

25. Raja M, Azzoni A. Diabetes is not a risk factor for tardive dyskinesia: a retrospective observational study. Hum Psychopharmacol. 2002 Jan;17(1):61-3. Abstract

26. Ganzini L, Casey DE, Hoffman WF, et al. Tardive dyskinesia and diabetes mellitus. Psychopharmacol Bull. 1992;28(3):281-6. Abstract

27. Pourcher E, Baruch P, Bouchard RH, et al. Neuroleptic associated tardive dyskinesias in young people with psychoses. Br J Psychiatry. 1995 Jun;166(6):768-72. Abstract

28. al-Adwani A. Brain damage and tardive dyskinesia. Br J Psychiatry. 1995 Sep;167(3):410-1.Full text  Abstract

29. Waddington JL, Youssef HA, Dolphin C, et al. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. Arch Gen Psychiatry. 1987 Oct;44(10):907-12. Abstract

30. Correll CU, Kane JM, Citrome LL. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry. 2017 Sep/Oct;78(8):1136-47.Full text  Abstract

31. National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. February 2020 [internet publication].Full text

32. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. March 2014 [internet publication].Full text

33. Lenka A, Jankovic J. Peripherally-induced movement disorders: an update. Tremor Other Hyperkinet Mov (N Y). 2023 Mar 28:13:8.Full text  Abstract

34. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988 Nov;39(11):1172-7. Abstract

35. Xu Y, Shi Q, Yue Y, et al. Clinical and imaging features of diabetic striatopathy: report of 6 cases and literature review. Neurol Sci. 2022 Oct;43(10):6067-77.Full text  Abstract

36. Espay AJ. Neurologic complications of electrolyte disturbances and acid-base balance. Handb Clin Neurol. 2014;119:365-82. Abstract

37. Chua CB, Sun CK, Hsu CW, et al. "Diabetic striatopathy": clinical presentations, controversy, pathogenesis, treatments, and outcomes. Sci Rep. 2020 Jan 31;10(1):1594.Full text  Abstract

38. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982 Apr;39(4):486-7. Abstract

39. Chakrabarty AC, Bennett JI, Baloch TJ, et al. Increasing Abnormal Involuntary Movement Scale (AIMS) screening for tardive dyskinesia in an outpatient psychiatry clinic: a resident-led outpatient Lean Six Sigma initiative. Cureus. 2023 May;15(5):e39486.Full text  Abstract

40. Jackson R, Brams MN, Carlozzi NE, et al. Impact-Tardive Dyskinesia (Impact-TD) scale: a clinical tool to assess the impact of tardive dyskinesia. J Clin Psychiatry. 2022 Nov 28;84(1):22cs14563.Full text  Abstract

41. Hawkins T, Berman BD. Pimavanserin: a novel therapeutic option for Parkinson disease psychosis. Neurol Clin Pract. 2017 Apr;7(2):157-62.Full text  Abstract

42. Bergman H, Rathbone J, Agarwal V, et al. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2018 Feb 6;(2):CD000459.Full text  Abstract

43. Bhidayasiri R, Jitkritsadakul O, Friedman JH, et al. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018 Jun 15;389:67-75. Abstract

44. Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. Front Neurol. 2022 Feb 23:13:773999.Full text  Abstract

45. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017 Aug;4(8):595-604. Abstract

46. Huntington Study Group, Frank S, Testa CM, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016 Jul 5;316(1):40-50.Full text  Abstract

47. Citrome L. Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017 Nov [Epub ahead of print].Full text  Abstract

48. Factor SA, Remington G, Comella CL, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study. J Clin Psychiatry. 2017 Nov/Dec;78(9):1344-50.Full text  Abstract

49. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017 May 1;174(5):476-84.Full text  Abstract

50. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007 Jan 15;22(2):193-7. Abstract

51. Bergman H, Bhoopathi PS, Soares-Weiser K. Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Jan 20;(1):CD000205.Full text  Abstract

52. Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997 Apr;17(2):88-91. Abstract

53. Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010 Nov-Dec;33(6):271-5. Abstract

54. van Harten PN, Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord. 2006 Aug;21(8):1276-7. Abstract

55. Slotema CW, van Harten PN, Bruggeman R, et al. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):507-9. Abstract

56. Anandan C, Jankovic J. Botulinum toxin in movement disorders: an update. Toxins (Basel). 2021 Jan 8;13(1):42.Full text  Abstract

57. Macerollo A, Deuschl G. Deep brain stimulation for tardive syndromes: systematic review and meta-analysis. J Neurol Sci. 2018 Jun 15;389:55-60. Abstract

58. McEvoy J, Gandhi SK, Rizio AA, et al. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual Life Res. 2019 Dec;28(12):3303-12.Full text  Abstract

59. Chong SA, Tay JA, Subramaniam M, et al. Mortality rates among patients with schizophrenia and tardive dyskinesia. J Clin Psychopharmacol. 2009 Feb;29(1):5-8. Abstract

60. Niemann N, Jankovic J. Treatment of tardive dyskinesia: a general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs. 2018 Apr;78(5):525-41. Abstract

61. Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov (N Y). 2014 Oct 23:4:266.Full text  Abstract